NervGen Pharma to Advance New Drug Candidate Into Preclinical Proof-of-Concept Stage

MT NewswiresJun 25 13:18 ET

NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus

Dow JonesMay 1 12:01 ET

NervGen Pharma Closes C$23 Million Bought Deal Financing

MT NewswiresMar 28 13:12 ET

NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units

MT NewswiresMar 21 16:10 ET

NervGen Pharma Extends the Expiry Date of Certain Stock Options

newsfileJun 2, 2023 18:15 ET

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Yahoo FinanceJan 6, 2023 06:02 ET